Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009918 · ClinicalTrials.gov registry record · Phase 2
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
A Phase 2 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 468
- Enrollment target
NCT01009918 is a Phase 2 study that has completed, run by University of South Florida. The registered enrollment target is 468 participants.
The verdict
NCT01009918, a Phase 2 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 468 participants
- Enrollment target
Study Summary
RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing side effects caused by trastuzumab. PURPOSE: This phase II trial is studying lisinopril and Coreg CR® to see how well they work compared with a placebo in reducing side effects in patients with HER2-positive breast cancer receiving trastuzumab.
Interventions
- OTHER placebo
- DRUG lisinopril
- DRUG Coreg CR®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2010-03 |
| Est. Completion | 2018-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009918
The ClinicalTrials.gov registry entry for NCT01009918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01009918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009918 about?
NCT01009918 is a clinical study titled "Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab". RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing side effects caused by trastuzumab. PURPOSE: This phase II trial is studying lisinopril and Coreg CR® to see how ...
What is the current status of trial NCT01009918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 468 participants. The study started on 2010-03. Estimated completion is 2018-11.
What interventions are being tested in trial NCT01009918?
The interventions under investigation include: placebo (OTHER), lisinopril (DRUG), Coreg CR® (DRUG).
Who is sponsoring clinical trial NCT01009918?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.